What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

• Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
• 11/05/2024

Viatris Announces Third Quarter 2024 Dividend

• PITTSBURGH , Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024.
• 11/05/2024

Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics

• Besides Wall Street's top -and-bottom-line estimates for Viatris (VTRS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
• 11/04/2024

Viatris Named to Forbes' World's Top Companies for Women 2024 List

• PITTSBURGH , Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider.
• 10/29/2024

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

• PITTSBURGH , Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the company will participate in two upcoming healthcare conferences. Details of the presentations can be found below: UBS Global Healthcare Conference Date: Tuesday, November 12, 2024 Time: 8:45 a.m.
• 10/29/2024

Idorsia announces financial results for the first nine months of 2024

• Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024.
• 10/29/2024

Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy

• Viatris Inc. stock has experienced significant volatility since its 2020 inception, driven by disappointing early performance, asset sales, and fluctuating market expectations. Despite low P/E and P/S ratios suggesting a “screaming buy,” falling revenues and substantial debt challenge Viatris' growth prospects. CEO Scott Smith's “Phase 2” strategy focuses on new product launches and debt reduction, aiming to offset declining sales of older generics and established brands.
• 10/22/2024

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

• -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments
• 10/16/2024

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

• Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH , Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe. Sotagliflozin was approved by the U.S. Food and Drug Administration in May 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
• 10/16/2024

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

• Treatment with once-daily EFFEXOR® met primary and all secondary efficacy endpoints in outpatient adults with GAD EFFEXOR® was generally well tolerated, consistent with its known safety profile Pharmaceuticals and Medical Devices Agency (PMDA) submission targeted for 2025 PITTSBURGH and TOKYO , Oct. 9, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR® (venlafaxine) in adults with generalized anxiety disorder (GAD). The study achieved its primary objective of superiority of anxiolytic effects of venlafaxine compared to placebo at 8 weeks, based on the change in the Hamilton Anxiety Rating Scale (HAM-A) total score from baseline (two-sided p-value=0.012).
• 10/09/2024

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row

• PITTSBURGH , Oct. 8, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024. This is the fourth year in a row that Viatris has received this recognition, which is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider.
• 10/08/2024

Viatris Announces the Pricing Terms of Maximum Tender Offer

• PITTSBURGH , Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") for up to an increased maximum aggregate principal amount of $575,003,000 of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes") validly tendered and not validly withdrawn at or prior to the Early Tender Date (as defined below) (such increased maximum aggregate principal amount, the "Maximum Tender Cap").
• 09/18/2024

Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer

• PITTSBURGH , Sept. 17, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the early tender results of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") and that UAS has increased the maximum aggregate principal amount for the Maximum Tender Offer from up to a maximum aggregate principal amount of $450,000,000 to up to a maximum aggregate principal amount of $575,003,000 (such increased aggregate principal amount, the "Maximum Tender Cap") of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes").
• 09/17/2024

Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024

• PITTSBURGH , Sept. 16, 2024  /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial markets.
• 09/16/2024

Viatris Announces Expiration and Results of Any and All Cash Tender Offers

• PITTSBURGH , Sept. 10, 2024  /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") (CUSIP No.
• 09/10/2024

Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers

• PITTSBURGH , Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") and any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris Notes, the "Any and All Notes").
• 09/10/2024

Viatris Announces Cash Tender Offers for Certain Outstanding Notes

• PITTSBURGH , Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acquisition" and, together with Viatris and Mylan, the "Offerors" and each, an "Offeror"), have commenced tender offers (each individually, with respect to a series of notes, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for cash (1) any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes"), (2) any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris Notes, the "Any and All Notes", and the tender offers with respect thereto, the "Any and All Tender Offers") and (3) up to $450,000,000 aggregate principal amount of the outstanding 3.950% Senior Notes due 2026 issued by Utah Acquisition (the "Maximum Tender Offer Notes", and the tender offer with respect thereto, the "Maximum Tender Offer", and the Maximum Tender Offer Notes together with the Any and All Notes, the "Securities").
• 09/04/2024

Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress

• Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be considered safe and well-tolerated Data shows a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies of cenerimod PITTSBURGH , Aug. 23, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, presented today the results of one of its Phase 2 studies* of cenerimod (ACT-333441). The ACT-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th Asia-Pacific League of Associations for Rheumatology (APLAR) Annual Congress.
• 08/23/2024

3 Top Value Stocks to Buy Right Now

• The S&P 500's Shiller P/E Ratio indicates an overvalued market. Value stocks may provide better returns in the current economic climate.
• 08/20/2024

Why Bargain-Priced Viatris Could Deliver Strong Returns

• Viatris is a pharmaceutical company with a diverse portfolio of branded drugs, generics, and biosimilars. It reported strong Q2 2024 performance with operational revenue growth, adjusted EBITDA, and EPS growth, while paying down debt and guiding for continued growth. Viatris offers a 4.2% dividend yield, with potential for future dividend increases and share buybacks, making it an attractive opportunity for income and value investors.
• 08/15/2024

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

• The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
• 08/09/2024

US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs

• On Thursday, Viatris Inc. VTRS reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.
• 08/08/2024

Why Viatris Stock Is Jumping Today

• Viatris reported Q2 revenue in line with Wall Street expectations. The healthcare company's Q2 adjusted earnings per share topped estimates.
• 08/08/2024

Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss

• Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
• 08/08/2024

Viatris (VTRS) Q2 Earnings Surpass Estimates

• Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.
• 08/08/2024

Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand

• Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs.
• 08/08/2024

Viatris Reports Second Quarter Financial Results for 2024

• PITTSBURGH , Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business  Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1] Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across Segments U.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was a Loss of $0.27 per Share; Adjusted EPS Grew ~3% to $0.69 per Share on a Divestiture-Adjusted Basis[2] Completion of Divestitures Marks Inflection Point in Company's Move Towards Accelerated Growth and Shareholder Return Raises 2024 Full-Year New Product Revenues Range to $500 Million-$600 Million Expects 2024 Full-Year Total Revenues Growth of ~2% on a Divestiture-Adjusted Operational Basis[3] Viatris Inc. (NASDAQ: VTRS) today announced strong financial results for the second quarter of 2024, including total revenues of $3.8 billion and new product revenues of $210 million, demonstrating the Company's ability to continue to grow its diversified base business.  With the substantial completion of its divestitures the Company believes it has increased its financial strength and has a strong foundation from which to accelerate growth and shareholder return.
• 08/08/2024

Viatris Announces Second Quarter 2024 Dividend

• PITTSBURGH , Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024, to shareholders of record as of the close of business on August 23, 2024.
• 08/06/2024

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

• Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
• 08/05/2024

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

• Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
• 08/05/2024

Seeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

• Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Viatris (VTRS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
• 08/05/2024

Earnings Preview: Viatris (VTRS) Q2 Earnings Expected to Decline

• Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
• 08/01/2024

3 Surprisingly Underrated Stocks to Buy Right Now

• AstraZeneca is a healthcare giant trading at a discount. There's more to the story with Pfizer than its COVID woes and looming patent cliff.
• 07/26/2024

Viatris Inc (VTRS:NAS) Company Profile: Analytics, Extensive Financial Metrics, and Benchmark Against Averages and Top Companies Within its Industry

• Dublin, July 26, 2024 (GLOBE NEWSWIRE) -- The "Viatris Inc (VTRS:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry" company profile from Plunkett Research Ltd has been added to ResearchAndMarkets.com's offering. This unique new report provides deep financial benchmarks for Viatris Inc (VTRS:NAS) compared to its top competitors and compared to the average for all companies within its primary industry. - This benchmarking study for Viatris Inc (VTRS:NAS) includes growth forecast for its primary industry for the current year and the next 7 years.
• 07/26/2024

Idorsia announces financial results for the first half 2024

• Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024.
• 07/25/2024

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

• With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
• 07/10/2024

Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture

• Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH , July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures. In October, the Company announced it had entered into agreements to divest substantially all of its OTC business, as well as its Women's Healthcare business, its Active Pharmaceutical Ingredients (API) business in India and commercialization rights in certain non-core markets.
• 07/03/2024

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

• Viatris said on Tuesday that its unit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry.
• 07/02/2024

U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation

• PITTSBURGH , July 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.
• 07/02/2024

Viatris Named to TIME's World's Most Sustainable Companies 2024 List

• PITTSBURGH , June 25, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to the inaugural edition of TIME's World's Most Sustainable Companies 2024. This recognition is presented by TIME and Statista Inc., the world-leading statistics portal and industry ranking provider.
• 06/25/2024

Viatris Inc. (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

• Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM ET Company Participants Scott Smith - CEO Theodora Mistras - CFO Philippe Martin - Chief R&D Officer Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Great. Why don't we get started?
• 06/11/2024

Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024

• PITTSBURGH , June 7, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the open of the U.S. financial markets. Chief Executive Officer  Scott A.
• 06/07/2024

Viatris Inc. (VTRS) Presents at Jefferies 2024 Global Healthcare Conference (Transcript)

• Viatris Inc. (NASDAQ:VTRS ) Jefferies 2024 Global Healthcare Conference Call June 6, 2024 8:00 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Well, good morning, everybody.
• 06/06/2024

Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

• PITTSBURGH , June 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, June 11, 2024. Chief Executive Officer Scott A Smith and Company executives will represent the company in a fireside chat scheduled at 9:20 a.m.
• 06/04/2024

Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors

• PITTSBURGH , June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors.
• 06/03/2024

Viatris to Participate in the Jeffries Global Healthcare Conference

• PITTSBURGH , May 31, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jeffries Global Healthcare Conference at the Marriott Marquis Hotel in New York, NY on Thursday, June 6, 2024. Chief Executive Officer Scott A.
• 05/31/2024

Viatris: Skeptics Proven Right Once Again

• Viatris Inc. reported Q1 2024 results in line with expectations, with a 2% decline in net sales. The company's EBITDA and free cash flow have been negatively impacted by declining sales, and its debt to EBITDA ratio remains high. Despite the low P/E ratio, Viatris stock has not delivered significant returns. We go into the reasons why.
• 05/30/2024

Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale

• Company continues to supply high-quality medicines to approximately 1 billion patients annually Report chronicles Viatris' commitment to providing access to healthcare and building healthier communities Impactful story highlights include "Empathy in Africa: Bridging the Healthcare Divide" – a powerful new documentary short that showcases Viatris' impact PITTSBURGH , May 21, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2023 Sustainability Report: Building Sustainable Access at Scale. The report highlights its actions and initiatives across multiple areas of focus in support of the Company's efforts to continue to be a model for sustainable access to medicine and to make a difference in the communities it serves.
• 05/21/2024

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

• Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024.
• 05/21/2024

Viatris Inc. (VTRS) BofA Securities 2024 Health Care Conference (Transcript)

• Viatris Inc. (NASDAQ:VTRS ) BofA Securities 2024 Health Care Conference May 14, 2024 1:00 PM ET Company Participants Doretta Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Jason Gerber - BoA Securities Jason Gerber All right, everybody, we're going to get going here with our next company presenter at the Bank Of America Annual Healthcare Conference. We got Viatris.
• 05/14/2024

Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down

• Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
• 05/09/2024

Viatris Inc. (VTRS) Q1 2024 Earnings Call Transcript

• Viatris Inc. (NASDAQ:VTRS ) Q1 2024 Earnings Call Transcript May 9, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Conference Call Participants Nathan Rich - Goldman Sachs Bhavin Patel - Bank of America Glen Santangelo - Jefferies Ash Verma - UBS Chris Schott - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning and welcome to Viatris Q1 2024 Earnings Conference Call. All participants will be in listen-only mode.
• 05/09/2024

Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

• While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
• 05/09/2024

Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates

• Viatris (VTRS) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago.
• 05/09/2024

Viagra maker Viatris misses revenue estimates on weak demand for older drugs

• Drugmaker Viatris narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure.
• 05/09/2024

Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges

• PITTSBURGH , May 9, 2024 /PRNewswire/ --  Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million; and Free Cash Flow of $565 Million for the First Quarter  Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1]  Reaffirms 2024 New Product Revenue Range of $450 Million to $550 Million   Closes Idorsia Transaction, Expanding Portfolio of Innovative Assets  Closes Women's Healthcare Business Divestiture  Reaffirms 2024 Financial Guidance After Adjusting the Ranges Solely to Reflect the Impact of Divestitures and Acquired IPR&D[2]  Returns $393 Million of Capital to Shareholders in First Quarter Through Dividends and Share Repurchases  Board of Directors Declares Quarterly Dividend of $0.12 per Share Viatris Inc. (NASDAQ: VTRS) today announced its financial results for the first quarter of 2024, which reflect continued momentum and the strength of its base business. Executive Commentary Viatris CEO Scott A.
• 05/09/2024

Why Earnings Season Could Be Great for Viatris (VTRS)

• Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
• 05/08/2024

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

• Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
• 05/06/2024

Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?

• Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
• 05/06/2024

Viatris (VTRS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

• Evaluate the expected performance of Viatris (VTRS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
• 05/06/2024

Viatris to Participate in the BofA Securities 2024 Health Care Conference

• PITTSBURGH , May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 14, 2024. Chief Financial Officer Doretta Mistras  and Chief R&D Officer Philippe Martin  will represent the company in a fireside chat scheduled at 10 a.m.
• 05/02/2024

Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?

• Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
• 05/02/2024

Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health

• PITTSBURGH and LONDON , May 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, recently launched Unmind as part of its global wellbeing program, Elevate. Unmind is a leading provider of workplace mental health solutions designed by psychologists to help individuals understand and be proactive with their mental health and lead healthier, happier lives.
• 05/01/2024

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

• The Inflation Reduction Act has reduced the exclusivity period for small-molecule drugs, potentially leading to earlier market entry for generic drugs. The shortened exclusivity period may create a bullish catalyst for certain stocks in the generic pharmaceutical sector. Gilead will face a patent "mini-cliff" in the near future, providing opportunities for generic drug manufacturers.
• 04/24/2024

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

• The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
• 04/18/2024

Viatris to Report First Quarter 2024 Financial Results on May 9, 2024

• PITTSBURGH , April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer  Scott A.
• 04/16/2024

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

• PITTSBURGH , April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally.
• 04/15/2024

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

• Viatris Inc. is a deep value pharmaceutical company with a low valuation and a 4.1% yield. Viatris has seen a slowdown in top line decline and has a promising pipeline of potential blockbuster drugs. Management is de-risking the balance sheet and returning capital to shareholders through dividends and share repurchases.
• 04/08/2024

UK watchdog says Theramex-Viatris deal raises competition concerns

• Britain's competition watchdog said Theramex's purchase of European rights to two of Viatris' women's healthcare products ranges could lead to higher prices and lesser options for hormone replacement therapy treatments.
• 04/04/2024

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

• Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine.
• 04/01/2024

Viatris Stock Is Still Worth Buying

• Viatris Inc. stock has risen by 26.7% since my November 2023 bullish call, outperforming the S&P 500 Index. It's time to update my thesis - read on. Although net sales declined (as did EBITDA and net profit) in 2023, we saw an improvement in the gross profit margin and a continuation of the deleveraging trend. The company has two new drugs ready for commercialization, Selatogrel and Cenerimod, which have significant growth potential, in my view.
• 03/30/2024

Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report?

• Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
• 03/29/2024

Viatris Inc. (VTRS) R&D Event (Transcript)

• Viatris Inc. (VTRS) R&D Event (Transcript)
• 03/27/2024

Is Viatris a Great Dividend Stock or Just a Value Trap?

• Viatris' high dividend yield and low valuation may look attractive to bargain hunters. However, the company's earnings nosedived last year, causing investor concern.
• 03/14/2024

2 Dirt Cheap Dividend Stocks to Buy and Hold

• Pfizer's slumping revenue is a temporary hiccup considering its incredibly deep pipeline. Viatris has made important changes to its business that should pay off down the road.
• 03/11/2024

US FDA declines to approve Viatris's injection for multiple sclerosis

• The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.
• 03/11/2024

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

• Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.
• 03/04/2024

Viatris Inc. (VTRS) Q4 2023 Earnings Call Transcript

• Viatris Inc. (VTRS) Q4 2023 Earnings Call Transcript
• 02/28/2024

Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates

• Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.
• 02/28/2024

Viatris (VTRS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

• While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
• 02/28/2024

3 Overextended Stocks That Need to Slash Their Dividends ASAP

• There are lots of overextended stocks out there falling short thanks to dividend payments that are too good to be true. The internationally known pharmaceutical company Bayer (OTCMKTS: BAYRY ) is a great example of this as the company recently announced a 95% dividend cut on Feb. 20.
• 02/27/2024

3 Bargain Stocks to Snatch Up Before They Bounce Back

• The momentum in technology stocks has buoyed the markets to new highs, leaving investors in a dilemma. Do they chase the hot AI and technology that have outperformed or stick with bargain stocks?
• 02/26/2024

Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?

• Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.
• 02/23/2024

Insights Into Viatris (VTRS) Q4: Wall Street Projections for Key Metrics

• Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
• 02/23/2024

Charts turn bullish on health-care stocks as sector takes early lead in 2024

• Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts have cited attractive valuations relative to earnings and a compelling growth story as two reasons health-care stocks might continue to outperform.
• 01/16/2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

• Viatris is an American pharmaceutical company formed as a result of the merger of Mylan and Upjohn. Over the past two and a half months, Viatris' share price has risen by more than 38%. Viatris' dividend yield is 3.97%, which is attractive because it is well above the sector median.
• 01/12/2024

Viatris Inc. (VTRS) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

• Viatris Inc. (VTRS) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
• 01/10/2024

Are defensive sectors ready to outshine growth in 2024?

• The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc. NASDAQ: MRNA, Merck & Co., Inc. NYSE: MRK and Viatris Inc. NASDAQ: VTRS.
• 01/06/2024

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

• Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
• 12/19/2023

Vertex's stock heads for all-time high as non-opioid painkiller shows promise

• Vertex Pharmaceuticals Inc. shares VRTX, +10.68% were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
• 12/13/2023

Viatris Stock Is Dirt Cheap And Worth Buying

• Viatris shares had a negative 25% total return in the past 2 years, underperforming the S&P 500. The decline is likely due to the company's debt burden and stagnant revenues. Despite this, now may be a good time to consider buying VTRS as its valuation is low and there are signs of future improvement in financial performance.
• 11/24/2023

7 Low P/E Stocks Poised to Rebound

• Screening for stocks with low price-to-earnings ratios is a great place to start when looking for value stocks, but your search for low P/E value stocks should not end there. That is, it's not as if you can screen for the stocks with the lowest P/E ratios, purchase them, and expect to generate outsized returns.
• 11/20/2023

Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip

• Viatris (VTRS) third-quarter earnings beat estimates. While brands maintain business, the Complex generics business performs below management's expectations.
• 11/08/2023

Viatris Inc. (VTRS) Q3 2023 Earnings Conference Call Transcript

• Viatris Inc. (NASDAQ:VTRS ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants William Szablewski - Head of Global Capital Markets Scott Smith - CEO Rajiv Malik - President Sanjeev Narula - CFO David Bayles - Chief Compliance Officer Brian Roman - Global General Counsel Conference Call Participants Christopher Schott - JPMorgan Nathan Rich - Goldman Sachs Umer Raffat - Evercore ISI Glenn Santangelo - Jefferies Jason Gerberry - Bank of America Ash Verma - UBS David Amsellem - Piper Sandler Operator Hello. My name is Travis, and I will be your conference operator today.
• 11/07/2023

Viatris (VTRS) Beats Q3 Earnings Estimates

• Viatris (VTRS) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.86 per share a year ago.
• 11/07/2023

Viatris core profit beats on generic drugs strength

• Viatris beat Wall Street estimates for third-quarter core profit on Tuesday, helped by strength in its generic drug portfolio, sending its shares up about 2% in extended trading.
• 11/07/2023

3 Large-Cap Stocks to Buy Trading Below Book Value

• A recent article about bond king Bill Gross' favorite banks got me thinking about large-cap stocks trading below book value. Gross liked these three bank stocks because they sold below book value and yielded 7% or more.
• 11/07/2023

Should You Buy Viatris (VTRS) Ahead of Earnings?

• Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
• 11/06/2023

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

• Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
• 11/06/2023

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

• Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
• 11/06/2023

Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?

• Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.
• 10/31/2023

Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?

• Viatris tried to invalidate three of the patents covering Novo Nordisk's Ozempic. The courts rebuffed two of those attempts, but the third will be evaluated in depth.
• 10/31/2023

Why Viatris (VTRS) is Poised to Beat Earnings Estimates Again

• Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
• 10/30/2023

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

• Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
• 10/30/2023

Viatris stock has no real catalysts; greater downside risk: analysts

• Viatris Inc's lack of discernable catalysts and greater downside risk is likely to weigh on the company's share price, according to BofA Securities analysts.   In an update to clients, they downgraded Viatris to ‘Underperform' and lowered their price objective on the stock to $9 per share from $13 on concerns over the company's 2024 outlook.
• 10/23/2023

Viatris: Get Paid 5%, Before Growth Materializes

• VTRS lost its Humira biosimilar through the divestiture of its biosimilar segment to Biocon, with the former similarly losing another growth prospects in Wegovy.
• 10/20/2023

Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?

• Viatris is advancing in its plan to become leaner and pay off its debt. To do so, it's offloading a trio of non-core business segments.
• 10/13/2023

Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023

• PITTSBURGH , Oct. 10, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its third quarter 2023 financial results on Tuesday, November 7 after the close of the U.S. financial markets. Chief Executive Officer Scott A.
• 10/10/2023

2 Top Value Stocks to Buy in October

• Value stocks should perk up if the Federal Reserve decides to maintain high interest rates in 2024. Philip Morris and Viatris are two plays that ought to benefit from this value tilt.
• 10/08/2023

2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip

• Medtronic offers impressive innovation, a strong position in healthcare, and an outstanding dividend history. Viatris is undergoing important changes that should lead to stronger financial results in the medium term.
• 10/08/2023

Drugmaker Viatris to divest some of its businesses

• Drugmaker Viatris said on Sunday that it has entered into agreements to divest its businesses, including the Women's Healthcare business and its Active Pharmaceutical Ingredients (API) business. It received an offer for the divestiture of its Over-the-Counter (OTC) business.
• 10/01/2023

Could Viatris Stock Help You Become a Millionaire?

• Viatris has a broad business that gives it many growth opportunities to pursue. The company is focusing on launching many products that can generate billions in revenue in the future.
• 09/30/2023

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

• Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.
• 09/28/2023

Viatris and Ocuphire Pharma get FDA green light for eye treatment

• Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis, or dilation of pupils. About 100 million eye dilations are conducted in the U.S. each year to examine the retina and for other routine check-ups, the companies said in a release, but the dilation can last up to 24 hours and side effects include light sensitivity and blurred vision.
• 09/27/2023

Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks

• High-yielding stocks can give you extra cash to help offset the impact of inflation. Many stocks are yielding far higher than 4%, including Viatris, Verizon, and Altria.
• 09/14/2023

Why 5%-Yielding Viatris Hasn't Doubled Yet

• Viatris is a healthcare corporation formed through a merger, with a diversified global portfolio and a focus on ophthalmology, gastrointestinal, and dermatology therapeutic areas. Despite its elevated debt load, Viatris has demonstrated strong financial performance, including revenue growth and high free cash flow, supporting its strategic progress and dividend sustainability. Trading at low multiples of EBITDA and free cash flow, Viatris stock presents a long-term investment opportunity, but its valuation improvement may take several years.
• 09/14/2023

Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?

• Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
• 09/06/2023

Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids

• Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.
• 09/05/2023

CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know

• CVS Health is getting into the biosimilar drug business that Viatris just exited. CVS could potentially target other types of generic medicines next.
• 09/01/2023

Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

• Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
• 08/31/2023

Viatris Stock: Bear vs. Bull

• Viatris is trying to launch generic versions of Novo Nordisk's Ozempic and Wegovy. It should experience an uptick in growth soon, and the stock's valuation is cheap.
• 08/31/2023

Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross

• From a technical perspective, Viatris Inc. (VTRS) is looking like an interesting pick, as it just reached a key level of support. VTRS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
• 08/30/2023

Dividend Stock Watch List: Lanny's September 2023 Edition

• The stock market, specifically the S&P 500, is still lurking over 4,400, up 16% this year. UPS is projecting to earn between $85 billion to $100 billion in revenue, just large amounts, even during a tough year that we have all been through. Similar to UPS, CM is getting crushed, down almost 9% in the last month and officially below the $40 mark.
• 08/28/2023

Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris

• One of these high-yield pharma stocks stands out as a better buy right now.
• 08/24/2023

Where Will Viatris Be in 5 Years?

• Viatris' near-term focus now is to reduce its heavy debt load. The company is also simplifying its business through more divestitures.
• 08/18/2023

Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?

• Viatris is trying to get its two generic versions of semaglutide approved for sale. Novo Nordisk is suing Viatris to prevent the approval from happening.
• 08/16/2023

Viatris: Turning Point For Cheap Pharma Stock

• Viatris reported strong second-quarter earnings, beating estimates on both revenue and earnings per share. The company showed signs of sales growth on a divestiture adjusted basis and is on track for $500 million of new product revenue. Management is committed to 9% of shareholder returns through dividends and buybacks, which can create momentum going into 2024.
• 08/11/2023

Is Viatris Stock Good for Dividend Income?

• Viatris is paying down its debt and planning to return capital to shareholders too. The generic drugmaker's growth hasn't been very impressive so far.
• 08/09/2023

Viatris (VTRS) Reports Q2 Earnings: What Key Metrics Have to Say

• While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
• 08/07/2023

S&P 500 Gains and Losses Today: Stocks Take Off After Earnings Reports

• The S&P 500 snapped a four-day losing streak on Monday, Aug. 7, 2023, rising 0.9% after the latest round of earnings reports.
• 08/07/2023

Viatris Shares Gain on Sales, Divestitures, and FDA Review of Its MS Drug

• Viatris shares advanced after the drugmaker posted better-than-expected results, said it will announce one or more divestitures this quarter, and indicated the FDA agreed to consider approval of its new multiple sclerosis treatment produced with Israel's Mapi Pharma.
• 08/07/2023

Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows

• Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.
• 08/07/2023

Markets Mixed at Midday on New Earnings Reports, Upcoming Data

• U.S. equities were mixed at midday on Monday, Aug. 7, 2023, after the latest earnings reports and ahead of key inflation data due later in the week.
• 08/07/2023

Viatris Inc. (VTRS) Q2 2023 Earnings Call Transcript

• Viatris Inc. (NASDAQ:VTRS ) Q2 2023 Earnings Call Transcript August 7, 2023 8:30 AM ET Company Participants William Szablewski - Head of Global Capital Markets Scott Smith - Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Jeff Nau - Eye Care Division Conference Call Participants Glenn Santangelo - Jefferies Jason Gerberry - Bank of America Ash Verma - UBS David Amsellem - Piper Sandler Umer Raffat - Evercore ISI Nathan Rich - Goldman Sachs Operator Good morning. My name is Todd, and I will be your conference operator today.
• 08/07/2023

Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates

• Viatris (VTRS) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.88 per share a year ago.
• 08/07/2023

Viatris beats second-quarter revenue estimates, says divestiture plans on track

• Viatris Inc beat Wall Street estimates for second-quarter revenue on Monday, on the strength of its branded drug portfolio, sending its shares up 2% in premarket trading.
• 08/07/2023

Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years

• Viatris is an appealing stock for dividend investors. Its business model should be sufficient to deliver long-term growth.
• 08/04/2023

Deerfield Management Company, L.P.

• Deerfield Management Company, L.P. (Series C), a renowned investment firm, recently made a significant addition to its portfolio.
• 08/01/2023

Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?

• Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.
• 07/31/2023

Dividend Stock Watch List: Lanny's August 2023 Edition

• Dividend Stock Watch List: Lanny's August 2023 Edition
• 07/29/2023

You can still run with the stock market's bulls, but watch the exits

• The stock market, as measured by the S&P 500 Index SPX, -0.64% ), has been moving upward. The U.S. benchmark index is essentially crawling up the higher “modified Bollinger Bands” (mBB), which is a bit of an overbought condition, but not a sell signal.
• 07/27/2023

Viatris Stock: Bull vs. Bear

• Investors like Viatris for its dividend and low valuation. Still, Viatris sales right now are on the decline.
• 07/22/2023

1 Reason I Wouldn't Buy This High-Yielding Dividend Stock

• Viatris offers investors a high dividend yield of 4.7%. The company's underlying business, however, has struggled to generate growth.
• 07/20/2023

Better Pharma Buy: Viatris vs. Pfizer

• Viatris has filled its pipeline with promising products -- that could add billions to revenue. Pfizer aims to launch a record number of drugs over the coming year or so.
• 07/19/2023

Viatris: Developing Into A Fantastic Investment Opportunity

• Viatris Inc. has a low valuation with a forward P/E of under 4 and a market cap of over $12 billion, predicted to reach $15.75 billion in revenues by 2023. The company recently acquired Oyster Point Pharma and Famy Life Sciences, expanding its exposure to the eye care market, and has a strong free cash flow (FCF) for further acquisitions. Despite a significant debt burden, Viatris has managed to reduce its long-term debt by over 25% through strategic divestitures and strong FCF generation.
• 07/18/2023

Better High-Yield Dividend Stock: Altria or Viatris?

• Tobacco giant Altria and generic drug specialist Viatris sport enormous dividend yields right now. In this head-to-head comparison, Viatris stands out as the better overall buy.
• 07/15/2023

3 Reasons to Buy Viatris Stock, and 1 Reason to Sell

• Viatris is making good progress on its strategic plan to cut its debt. It's also going to have more money to give back to investors relatively soon.
• 07/14/2023

3 Healthcare Stocks With Healthy Dividends

• The stocks' shares have all declined to begin the year. Each company had a sluggish first quarter, but has a pipeline with plenty of potential.
• 07/13/2023

3 Beaten-Down Dividend Stocks That Look Like Bargains Right Now

• Viatris is a generic drugmaker formed from a merger between Pfizer's generic drug division and Mylan. CVS Health is famous for its pharmacy chain, but it's the parts of its business you might not know about that make it a great dividend stock.
• 07/10/2023

3 Stocks to Snag for Less Than Book Value

• The move to share repurchases over the last few years has made the price-to-book ratio less reliable for finding hidden opportunities in stocks. How's that, you ask?
• 07/07/2023

Why Dividend Stocks Should Be a Key Part of Your Retirement Plan

• If you worry you won't have enough saved up by retirement, dividend stocks can help boost your income. Allocating part of your retirement savings to such equities can reduce depletion of your savings.
• 07/07/2023

Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?

• Viatris is growing while slashing costs and returning capital to investors. It has plans to onboard even more new sources of revenue, but it'll take a while.
• 07/05/2023

Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023

• PITTSBURGH , June 28, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open of the U.S. financial markets. Chief Executive Officer  Scott A.
• 06/28/2023

Fresh Blood: 3 Stocks Ready to Rally Under New CEOs

• In recent years, S&P 500 companies with new chief executive officers (CEOs) have become a regular occurrence. That's because CEOs are moving on more quickly — both by choice and because of activist investors — and that means there are always interesting possibilities for stocks set to rally under new CEOs.
• 06/28/2023

Viatris (VTRS) Flat As Market Gains: What You Should Know

• Viatris (VTRS) closed the most recent trading day at $9.85, making no change from the previous trading session.
• 06/27/2023

Barclays Downgrades Viatris

• Fintel reports that on June 23, 2023, Barclays downgraded their outlook for Viatris (NASDAQ:VTRS) from Equal-Weight to Underweight.
• 06/23/2023

The Wonders of Shareholder Yield

• Shareholder Yield is a composite metric which measures potential shareholder returns. Many investors are not terribly familiar with this metric, preferring to pay attention to dividends alone.
• 06/16/2023

Viatris: Won't Take Much To Move The Needle

• Viatris remains a dirt cheap stock in a frothy market and pays a well-covered dividend yield. It continues to make progress towards deleveraging, and could return substantial capital to shareholders in 2024. With market sentiment working against the stock, it could deliver potentially strong total returns for investors should the tide change.
• 06/15/2023

Viatris Inc. (VTRS) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

• Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 44th Annual Global Healthcare Conference June 13, 2023 4:20 PM ET Company Participants Scott Smith - CEO Rajiv Malik - President Sanjeev Narula - CFO Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Great. Well, good afternoon, everyone.
• 06/13/2023

These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys

• Viatris generates ample cash flow to pay down its debt and support its above-average dividend yield. Enbridge's payout ratio based on net income may look alarming, but the company's dividend is safer than it looks.
• 06/08/2023

Why Is Viatris (VTRS) Down 2.4% Since Last Earnings Report?

• Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
• 06/07/2023

Looking for Passive Income at a Decent Price? Buy These 2 Stocks

• High-quality dividend stocks typically aren't cheap. Viatris has a great roster of medicines on the market, with more generics to come.
• 06/05/2023

Our acquisition of Viatris business has been 'spooking the Indian investor,' biotechnology firm says

• Kiran Mazumdar-Shaw of Biocon & Biocon Biologics discusses the company's acquisition of Viatris' biosimilars business and says Indian investors are "very wary" of overseas acquisitions and there was a "huge debt component."
• 05/25/2023

It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?

• Viatris pays a decent dividend and its line of business should be relatively safe. But it hasn't yet demonstrated its ability to maintain a stable top or bottom line.
• 05/18/2023

Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

• Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
• 05/08/2023

Viatris Inc. (VTRS) Q1 2023 Earnings Call Transcript

• Viatris Inc. (NASDAQ:VTRS ) Q1 2023 Results Conference Call May 8, 2023 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - Incoming Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Conference Call Participants Glenn Santangelo - Jefferies Chris Schott - JPMorgan Balaji Prasad - Barclays David Amsellem - Piper Sandler Ash Verma - UBS Umer Raffat - Evercore ISI Nathan Rich - Goldman Sachs Group Operator Good morning. My name is Gretchen, and I will be your conference operator today.
• 05/08/2023

Viatris (VTRS) Tops Q1 Earnings Estimates

• Viatris (VTRS) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.93 per share a year ago.
• 05/08/2023

Want to Collect $1,100 in Dividends? Invest $20,000 in These 2 Stocks

• Viatris' business didn't grow at all last year, but the company's free cash flow is strong enough to support (and boost) its dividend payments. AT&T is coming off a tough quarter that spooked investors, but the telecom continues to expand, making it an underrated dividend stock.
• 04/27/2023

4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates

• Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).
• 04/25/2023

8 Defensive Plays as Healthcare Stocks Stumble

• Healthcare stocks have sputtered this year after performing well in 2022. A Barron's screen has identified stocks that are poised to outperform for the rest of the year.
• 04/19/2023

Wall Street Thinks These 2 Value Stocks Could Soar

• Continued Medicaid expansion bodes well for Centene. Viatris' drug pipeline should deliver modest growth in the years ahead.
• 04/17/2023

1 "Safe" Stock to Avoid and 1 to Consider Buying in April

• In theory, the stock of companies that make generic drugs have the potential to be safe investments. Despite that, companies like Teva Pharmaceuticals aren't actually safe at all.
• 04/15/2023

The 7 Most Undervalued Nasdaq Stocks to Buy in April 2023

• Given the high concentration of tech and other types of growth plays trading on the Nasdaq exchange, it's easy to conflate the term “Nasdaq stocks” with growth stocks. However, there are in actuality scores of undervalued Nasdaq stocks—And not just in the sense of “relative value.
• 04/04/2023

Which Is the Better Dividend Stock: Viatris or Apple?

• Viatris isn't growing quickly, but its dividend yield is high at the moment. Apple is growing steadily, and it has a long history of paying out to shareholders.
• 03/31/2023

Generic drugs are most likely to face shortages due to market failures in affordability

• CNBC's Meg Tirrell joins 'Closing Bell Overtime' to discuss growing pharmaceutical shortages, increasing debt hindering generic drug availability, and more.
• 03/29/2023

Why Is Viatris (VTRS) Down 16.4% Since Last Earnings Report?

• Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
• 03/29/2023

Don't Be Fooled by These 3 Value Traps

• In stock investing, these are called value traps. Value traps are equities that appear to be inexpensive because they have low valuations.
• 03/28/2023

Viatris: The Value And The Value Trap

• To say Viatris has been a sore disappointment since its spin-off, would be a massive understatement. The company came into its listing on very low valuations and had to do very little right to deliver average returns.
• 03/26/2023

3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential

• Embecta should benefit from the greater need for diabetic services. Viatris is focusing on finding new generics.
• 03/26/2023

Is Viatris' 5% Dividend Yield Safe?

• Viatris has been paying down debt, but investors remain wary of investing in the company. Interest costs, however, haven't been crippling the business.
• 03/21/2023

Better Generics Pharmaceutical Stock: Teva or Viatris?

• Teva is the world's largest maker of generic drugs. Viatris offers an above-average dividend yield.
• 03/05/2023

Viatris: Too Cheap To Ignore

• Viatris recently closed out 2022 having largely met management's prior guidance. It's aggressively paying down debt and recent acquisitions may drive meaningful growth down the road.
• 03/01/2023

Viatris' (VTRS) Q4 Earnings In-Line, Revenues Miss Estimates

• Viatris (VTRS) reports in-line Q4 earnings but misses on sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
• 02/27/2023

Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

• While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
• 02/27/2023

VTRS Stock Alert: What to Know as Viatris Appoints New CEO

• Viatris (NASDAQ: VTRS ) stock is in the news Monday after the healthcare company announced Scott Smith as its next CEO. This will see Smith take over as the next CEO of Viatris on April 1, 2023.
• 02/27/2023

Viatris (VTRS) Matches Q4 Earnings Estimates

• Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
• 02/27/2023

Francisco Garcia Parames' Cobas Funds 4th-Quater Letter

• Dear Investor:
• 02/22/2023

What To Expect From Viatris In 2023

• Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022.
• 02/22/2023

3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later

• These pharmaceutical stocks probably won't stay so attractively valued for too much longer.
• 02/18/2023

Competition Coming For AbbVie's Blockbuster Humira

• It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
• 02/16/2023

Don't Buy Viatris And Organon Just Because Of The Dividends

• Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies. While I have already reported on Viatris' ever-changing portfolio, in this article I will take a closer look at Organon's portfolio and highlight the differences in strategy.
• 02/13/2023

2 Superb Dividend Stocks to Buy Today and Hold Forever

• These two companies have long runways for growth and decent yields today.
• 01/24/2023

Viatris: Where Is The Cure?

• Viatris has seen a disappointing performance since its 2019 mega tie-up. Sales and EBITDA have fallen a bit, as leverage has fallen a bit further.
• 01/23/2023

Could This New Drug Launch Be a Hit for Viatris?

• Viatris and Kindeva Drug Delivery could soon launch a generic version of AstraZeneca's Symbicort.
• 01/12/2023

Viatris Inc. (VTRS) 41st Annual J.P. Morgan Healthcare Conference (Transcript)

• Viatris Inc. (NASDAQ:VTRS ) 41st Annual J.P. Morgan Healthcare Conference January 11, 2023 6:00 PM ET Company Participants Michael Goettler - CEO Rajiv Malik - President Jeffrey Nau - Head, Eye Care Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon.
• 01/11/2023

Is Now the Time to Buy 3 of the S&P 500's Cheapest Stocks?

• All of these stocks are trading at less than 7 times their future profits.
• 01/04/2023

Why These 7 Healthcare Stocks Could Soar in 2023

• With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.
• 01/02/2023

1 Passive Income Stock to Buy While It's Cheap and 1 to Avoid

• Both businesses are well-suited for producing passive income, but only one has the balance sheet and future prospects to make it work.
• 12/29/2022

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond

• Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks.
• 12/18/2022

Want $3,000 in Dividend Income Next Year? Invest $50,000 in These 2 Stocks

• These stocks have dividend yields exceeding 4%.
• 12/07/2022

Better Dividend Stock: AbbVie or Viatris?

• These pharmaceutical companies are profitable and offer above-average dividends.
• 11/26/2022

3 Stocks With Dividends of 3% or More to Buy on the Dip

• Three underpriced healthcare stocks provide an opportunity.
• 11/14/2022

Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort

• Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.
• 11/11/2022

Viatris Executive Charged With Insider Trading

• Prosecutors and regulators say Ramkumar Rayapureddy, global chief information officer, tipped a friend about a regulatory drug approval.
• 11/10/2022

Want to Collect a High Dividend Every Month? Buy These 3 Stocks

• Together, these stocks will ensure you're receiving a dividend each month of the year.
• 11/10/2022

Making Sense of the Earnings Picture and Estimate Revisions

• Looking at 2022 Q3 as a whole, total S&P 500 earnings are currently expected to be up +1.5% from the same period last year on +11.4% higher revenues. Excluding contributions from the Energy sector, Q3 earnings for the rest of the index would be -6.0%
• 11/09/2022

Making Sense of the Earnings Picture and Estimate Revisions

• Looking at 2022 Q3 as a whole, total S&P 500 earnings are currently expected to be up +1.5% from the same period last year on +11.4% higher revenues. Excluding contributions from the Energy sector, Q3 earnings for the rest of the index would be -6.0%
• 11/09/2022

Viatris: A Spinoff That Got Even More Interesting

• Viatris' business is holding up better than expected, despite FX headwinds. A new path to growth clears visibility for investors as the company targets to be the next ophthalmology leader.
• 11/09/2022

Why Viatris (VTRS) Is Buying Oyster Point (OYST)

• Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.
• 11/07/2022

Viatris Inc. (VTRS) Q3 2022 Earnings Call Transcript

• Viatris Inc. (NASDAQ:VTRS ) Q3 2022 Results Conference Call November 7, 2022 8:30 AM ET Company Participants Bill Szablewski - Head of Global Capital Markets Robert Coury - Executive Chairman Michael Goettler - Chief Executive Officer Rajiv Malik - President Dr. Jeff Nau - Oyster Point CEO Sanjeev Narula - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond James Umer Raffat - Evercore Chris Schott - JPMorgan Gary Nachman - BMO Capital Markets Ash Verma - UBS Jason Gerberry - Bank of America Glenn Santangelo - Jefferies Greg Fraser - Truist Securities Nathan Rich - Goldman Sachs David Amsellem - Piper Sandler Operator Good morning. My name is Gretchen, and I will be your conference operator today.
• 11/07/2022

Viatris (VTRS) Q3 Earnings Beat, Revenues Miss Estimates

• Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.
• 11/07/2022

Why Viatris Stock Is Jumping Today

• Investors are applauding a key step in Viatris' plans to return to growth.
• 11/07/2022

Why Viatris Shares Are Soaring Higher - Viatris (NASDAQ:VTRS)

• Viatris Inc (NASDAQ: VTRS) shares are trading higher by 16.80% to $11.33 Monday morning after the company announced it will acquire Oyster Point Pharma. What Happened?
• 11/07/2022

Viatris (VTRS) Stock Pops 17% on Acquisition News

• Viatris (NASDAQ: VTRS ) issued a press release today with a slew of good news. For one thing, Viatris is acquiring two different businesses.
• 11/07/2022

Viatris (VTRS) Q3 Earnings Beat Estimates

• Viatris (VTRS) delivered earnings and revenue surprises of 4.88% and 1.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
• 11/07/2022

Vanguard Health Care Fund Exits Viatris, Plugs Into GSK in 3rd Quarter

• The Vanguard Health Care Fund (Trades, Portfolio) disclosed in a regulatory filing that its top trades during the third quarter included the closure of its positions in Viatris Inc. ( VTRS , Financial) and Universal Health Services ( UHS , Financial), a reduction to its holding in Vertex Pharmaceuticals Inc. ( VRTX , Financial), a new holding in GSK PLC ( LSE:GSK , Financial) and a boost to its holding in DexCom ( DXCM , Financial).
• 11/04/2022

Viatris Asset Disposals Make The Value Case For Their Branded Portfolio

• In the latest quarter, ignoring the quite severe effects of the dollar's appreciation, Viatris' brands performed well. But even for biosimilars, Viatris is proving portfolio value in the sale of that portfolio for a more than 10x multiple.
• 10/30/2022

Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022

• PITTSBURGH , Oct. 24, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022. Executive Chairman Robert J.
• 10/24/2022

3 Healthcare Stocks That Are Too Cheap to Ignore

• They all offer attractive dividends, too.
• 10/22/2022

3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later

• Procrastination could be problematic with these three bargain stocks.
• 10/22/2022

Should I invest in Viatris shares after the current dip?

• Viatris Inc. (NASDAQ: VTRS) shares have weakened from $10.20 to $8.42 since September 12, 2022, and the current price stands at $8.74. The U.S. stock market remains under pressure, and going forward, it will be hypersensitive to any FED comments.
• 10/08/2022

October 2022 Stock Considerations

• The silver lining amid the market collapse is that every new dollar put to work today in dividend stocks comes with an automatic higher yield when compared to just a few weeks ago. First up, I'm thinking about adding to recent spin-off Viatris Inc.
• 10/03/2022

Take These Broken Wings And Learn To Fly Again Viatris

• We were cautious on Viatris as we felt the three headwinds we anticipated would lead to a guidance cut. We were partially correct on that outcome, but the stock still went lower despite holding the free cash flow outlook.
• 09/25/2022

Drugmaker stocks lead sector with healthy dividends

• CNBC's Bertha Coombs reports on health care stocks.
• 09/23/2022

Health care stocks with dividend yields to weather through market turmoil

• The healthcare sector is an investor favorite in a defensive market. CNBC's Bertha Coombs joins 'Squawk Box' to break down some players with the best dividend yields.
• 09/23/2022

Merck Stock Surges After Winning Patent Battle Vs. Viatris Over Two Key Drugs

• Merck stock jumped Thursday after the company won a patent battle against generic-drug maker Viatris over an ingredient used in diabetes meds. The post Merck Stock Surges After Winning Patent Battle Vs.
• 09/22/2022

Viatris Inc.'s (VTRS) BofA Global Research Global Healthcare Conference Transcript

• Viatris Inc. (NASDAQ:VTRS ) BofA Global Research Global Healthcare Conference September 15, 2022 11:45 AM ET Company Participants Michael Goettler – Chief Executive Officer Rajiv Malik – President Sanjeev Narula – Chief Financial Officer Conference Call Participants Jason Gerberry – BofA Securities Jason Gerberry Well, good day, everybody. Thanks for joining us at the BofA London Healthcare Conference.
• 09/15/2022

7 Screaming Buy Stock Picks to Beat the September Market Slump

• Finding stock picks to beat the market are rare finds nowadays. In September stock markets began on downbeat momentum following the S&P 500 rally throughout the summer.
• 09/13/2022

Is Viatris Stock a Buy Now?

• Its top-line troubles could be transient, but there's a risk they won't be.
• 09/12/2022

Making Healthcare More Efficient Could Benefit Select ETFs

• The U.S. doesn't have nationalized healthcare comparable to some other developed countries, and it is home to one of the most lumbering, inefficient healthcare systems. It would be to the benefit of healthcare providers, doctors, nurses, and investors if those inefficiencies were quashed.
• 09/07/2022

Viatris: 5% Dividend Yield Is A Threat For Investors

• Viatris's total revenue was $4,116.8 million in Q2 2022, down 10.1% year-on-year. Sales of the company's branded medicines have been declining since the formation of Viatris in 2020.
• 09/05/2022

3 of the Best Dividend Stocks to Buy in September

• From healthcare to oil and gas to telecom, these stocks can also help diversify your portfolio.
• 08/31/2022

This Beaten-Down Dividend Stock Is a Scorching-Hot Buy

• Viatris reported encouraging earnings numbers earlier this month.
• 08/19/2022

Should I sell Viatris shares after Q2 results failed to meet revenue expectations?

• Viatris Inc. (NASDAQ: VTRS) reported its second-quarter results on Monday and lowered the revenue outlook for the 2022 fiscal year. Michael Goettler, CEO of Viatris, said that because of strong operational performance, he believes that Viatris can absorb the foreign exchange rate impact within announced ranges.
• 08/14/2022

10 defensive stocks that can also provide you with growth and dividends over the long term

• The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.
• 08/10/2022

Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates

• Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
• 08/08/2022

Viatris Inc. (VTRS) CEO Michael Goettler on Q2 2022 Results - Earnings Call Transcript

• Viatris Inc. (NASDAQ:VTRS ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants Bill Szablewski - Head of Global Capital Markets Michael Goettler - Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond James Chris Schott - JPMorgan Umer Raffat - Evercore Gary Nachman - BMO Capital Markets Greg Fraser - Truist Securities Ash Verma - UBS David Amsellem - Piper Sandler Nathan Rich - Goldman Sachs Operator Good morning. My name is Leo, and I'll be your conference operator conference today.
• 08/08/2022

Viatris (VTRS) Surpasses Q2 Earnings Estimates

• Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
• 08/08/2022

Viatris Q2 Preview: Can Shares Snap Their Downtrend?

• Even over the last month, when the S&P 500 has rallied for an 8% gain, Viatris shares have continued their downwards trajectory, declining 5.5% in value.
• 08/05/2022

Earnings Previews: Barrick Gold, Palantir, Tyson Foods, Viatris

• The three major U.S. equity indexes closed higher Wednesday. The Dow Jones industrials added 1.29%, the S&P 500 increased by 1.56%, and the Nasdaq jumped by 2.59%.
• 08/04/2022

Viatris: A Spinoff To Own

• Viatris is down 40% since the spin-off. Financial metrics are positively increasing as one-time costs of the merger are decreasing. Safe and high dividend yield combined with exceptional free cash flow yield offer a great margin of safety.
• 08/01/2022

Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for

• Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
• 08/01/2022

2 Cheap Dividend Stocks Yielding More Than 4%

• These two companies haven't performed well in the market recently, but that could be an opportunity for investors.
• 07/31/2022

3 High-Yielding Dividend Stocks With Payout Ratios Over 100%

• Are these dividend payments at risk?
• 07/27/2022

Billionaires Are Piling Into These 2 Dividend-Paying Pharma Stocks

• Billionaires are taking advantage of the weakness in Pfizer and Viatris this year.
• 07/26/2022

7 Best Pharmaceutical Stocks to Buy Now

• These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.
• 07/20/2022

With Brighter Outlook, Generics Could Be Ripe for Investment

• Of the top 10 generic drugmakers in 2021, only one scored an increase in share price during the past year. It was Sun Pharmaceutical Industries Ltd.
• 07/18/2022

2 Deeply Discounted Dividend Stocks With High Yields

• These stocks pay a dividend yield of more than 4%.
• 07/06/2022

Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022

• PITTSBURGH , July 1, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets. Chief Executive Officer  Michael Goettler , President  Rajiv Malik , and Chief Financial Officer  Sanjeev Narula  also will host a webcast at 8:30 a.m.
• 07/01/2022

Organon Vs. Viatris: Who Is The Clear Winner?

• Organon's P/E ratio was 6.5 at the end of Q1 2022, significantly lower than the pharmaceutical industry average. Viatris' revenue was $4,191.7 million in the first quarter of 2022, down 5.4% from a year earlier.
• 06/19/2022

Viatris Inc. (VTRS) Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)

• Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 43rd Annual Global Healthcare Conference June 14, 2022 4:20 PM ET Company Participants Bill Szablewsk - Head, Capital Markets and IR Rajiv Malik - President Sanjeev Narula - CFO Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Hi everyone. Welcome to the afternoon sessions at our conference.
• 06/14/2022

Viatris (VTRS) Up 13.7% Since Last Earnings Report: Can It Continue?

• Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
• 06/08/2022

7 High-Quality Dividend Stocks With High Yields

• These are the best dividend stocks with high yields to invest in now. BIP, EPR, FL, KMI, KHC, VTRS, and WBA can make great investments.
• 06/07/2022

2 Bruised Dividend Stocks to Buy While They're Cheap

• Lower share prices won't stop them from hiking their dividends.
• 06/06/2022

Why Shares of Viatris Climbed 18.8% in May

• The company reported improved net income and free cash flow in the last quarter.
• 06/06/2022

3 Great Dividend Stocks to Buy in June

• Investors should be able to count on recurring income with these stocks.
• 06/05/2022

3 High-Yielding Dividend Stocks That Are Trading Below Their Book Values

• These stocks are incredibly cheap, and aren't as risky as their low multiples suggest they might be.
• 06/01/2022

Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

• PITTSBURGH , May 20, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA on Tuesday, June 14, 2022. Chief Executive Officer Michael Goettler , President Rajiv Malik and Chief Financial Officer Sanjeev Narula will represent the company in a fireside chat scheduled at 1:20 p.m.
• 05/20/2022

2 Stocks That Are Ridiculously Cheap Right Now

• They present very different kinds of bargains.
• 05/14/2022

3 Dirt-Cheap Stocks You Can Buy Right Now

• These stocks are inexpensive yet have solid underlying businesses.
• 05/14/2022

Viatris Inc.'s (VTRS) CEO Michael Goettler on Q1 2022 Results - Earnings Call Transcript

• Viatris Inc. (NASDAQ:VTRS ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Bill Szablewsk - Head, Global Capital Markets Michael Goettler - Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer Conference Call Participants Pavan Patel - Bank of America Merrill Lynch Elliot Wilbur - Raymond James Chris Schott - JPMorgan Umer Raffat - Evercore. Greg Fraser - Truist Securities Nate Rich - Goldman Sachs David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Operator Good morning.
• 05/09/2022

Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

• Viatris Inc (NASDAQ: VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Lipitor, Effexor, and Perforomist.
• 05/09/2022

Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

• Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
• 05/09/2022

Why Viatris Stock Is Popping Today

• The drugmaker handily beat Wall Street earnings expectations in the first quarter.
• 05/09/2022

Viatris (VTRS) Q1 Earnings Beat Estimates

• Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
• 05/09/2022

Viatris: A Cigar Butt With Many Puffs Left

• By selling its only growth asset, Viatris has turned out to be a cigar butt investment that still has many puffs left in it due to its strong free cash flow. Debt remains a concern, but the company continues to deleverage thanks to its strong free cash flow and has accelerated the process through the announced asset sale.
• 05/09/2022

Earnings Preview: Viatris (VTRS) Q1 Earnings Expected to Decline

• Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
• 05/02/2022

Want Extra Income Every Month? Invest in These 3 High-Yielding Dividend Stocks

• Boost your portfolio's balance with these solid, income-generating investments.
• 04/28/2022

Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022

• PITTSBURGH , April 8, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2022 financial results on Monday, May 9, before the open of the U.S. financial markets. Chief Executive Officer  Michael Goettler , President  Rajiv Malik , and Chief Financial Officer  Sanjeev Narula  also will host a webcast at 8:30 a.m.
• 04/08/2022

Viatris (VTRS) Up 10.2% Since Last Earnings Report: Can It Continue?

• Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
• 03/30/2022

2 Dirt Cheap Dividend Stocks to Buy Right Now

• These two bargain stocks look like steals right now.
• 03/29/2022

7 Cheap Stocks to Buy Now if You Have $100 to Spend

• The S&P 500 is off to a forgettable start this year, but that creates multiple buying opportunities if you're looking for cheap stocks. The post 7 Cheap Stocks to Buy Now if You Have $100 to Spend appeared first on InvestorPlace.
• 03/22/2022

3 Dividend Stocks That Could Soar 34% to 54%, According to Wall Street

• The stocks have fallen quite a bit, but analysts look for strong rebounds.
• 03/20/2022

Viatris Inc. (VTRS) CEO Mike Goettler Presents at 2022 Barclays Global Healthcare Conference (Transcript)

• Viatris Inc. (VTRS) CEO Mike Goettler Presents at 2022 Barclays Global Healthcare Conference (Transcript)
• 03/16/2022

Viatris (VTRS) Gains But Lags Market: What You Should Know

• Viatris (VTRS) closed the most recent trading day at $9.96, moving +1.53% from the previous trading session.
• 03/15/2022

Why is Viatris (VTRS) Stock Down 25% in the Year So Far?

• Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.
• 03/11/2022

Viatris: Takeaways From Management At The Raymond James Conference

• Did the biosimilars deal because they saw business slowing and wanted to create a low cost vertically-integrated player.
• 03/10/2022

Is Viatris Stock in Trouble?

• The stock crashed after the company reported earnings.
• 03/10/2022

Viatris Inc. (VTRS) CEO Michael Goettler Presents at Raymond James 43rd Annual Institutional Investors Conference (Transcript)

• Viatris Inc. (VTRS) CEO Michael Goettler Presents at Raymond James 43rd Annual Institutional Investors Conference (Transcript)
• 03/08/2022

Why Viatris Stock Dropped 24% in February

• Investors were unimpressed with the company's middling fourth-quarter earnings report.
• 03/08/2022

3 New Reasons to Sell Viatris Stock Right Now

• Its latest earnings report is full of red flags.
• 03/07/2022

Is It Time to Buy the S&P 500's 5 Worst-Performing February Stocks?

• Before plowing into some well-known names just because they've seen extreme price drops, take a step back and look at the bigger picture.
• 03/05/2022

Want to Be a Contrarian Investor? Buy Viatris Stock Now

• After the stock's sharp downturn, there's a juicy opportunity waiting for daring investors.
• 03/04/2022

Viatris Just Snagged a Major FDA Approval

• This recently approved generic drug could benefit 5% to 15% of the overall population.
• 03/03/2022

Is Viatris a good buy opportunity after the current dip?

• Viatris Inc. (NASDAQ: VTRS) shares have weakened more than 20% after the company reported fourth-quarter results this Monday. Fourth-quarter results and revenue outlook disappointed several banks and research companies, which lowered their price targets on Viatris shares.
• 03/01/2022

Viatris Stock: Why So Serious? Let's Put A Buy On Your Portfolio

• Viatris Stock: Why So Serious? Let's Put A Buy On Your Portfolio
• 03/01/2022

Viatris, Inc. (VTRS) CEO Michael Goettler on Q4 2021 Results - Earnings Call Transcript

• Viatris, Inc. (VTRS) CEO Michael Goettler on Q4 2021 Results - Earnings Call Transcript
• 02/28/2022

Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver

• Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its business following a strategic review.
• 02/28/2022

Viatris: Perhaps An Overreaction

• Viatris reported Q4-2021 results and gave mediocre guidance for 2022.
• 02/28/2022

Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters

• Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has agreed to pay $264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment. The proposed settlement would resolve litigation following public.
• 02/28/2022

Here's Why Viatris Stock Is Sliding on Monday

• Earnings that missed expectations and a soft outlook for 2022 disappointed investors.
• 02/28/2022

Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked

• Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.
• 02/28/2022

My Investment Thesis On Viatris Remains Intact After The Sale Of The Biosimilars Assets

• Viatris reported solid fiscal 2021 earnings, after having increased guidance on multiple occasions.
• 02/28/2022

India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal

• Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ: VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value includes cash of up to $2.335 billion and Compulsorily Convertible Preference Shares in Biocon Biologics, valued at $1.
• 02/28/2022

Viatris (VTRS) Q4 Earnings Miss Estimates

• Viatris (VTRS) delivered earnings and revenue surprises of -2.44% and 0.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
• 02/28/2022

Viatris to settle EpiPen antitrust litigation for $264 million

• (Reuters) -Viatris Inc, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment.
• 02/28/2022

Viatris to contribute its biosimilars portfolio to Biocon Biologics for up to $3.335 billion, shares jump 4% premarket

• Viatris Inc. VTRS, +4.38% , the company formed by the merger of Mylan and Pfizer Inc. PFE, +3.83% unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd. for up to $3.335 billion.
• 02/28/2022

Why Viatris (VTRS) Might Surprise This Earnings Season

• Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
• 02/25/2022

Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?

• Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
• 02/21/2022

Viatris Vs. Organon: Surprisingly Undervalued, But Which Is The Better Buy?

• Viatris was formed by the merger of Pfizer's Legacy Brands business Upjohn with generic drug developer Mylan.
• 02/19/2022

Why Viatris (VTRS) Could Beat Earnings Estimates Again

• Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
• 02/09/2022

7 Discounted Dividend Stocks With Market-Beating Yields

• While there is ample supply of dividend stocks to be found on Wall Street, finding high-quality ones whose payouts are secure can be a little more tricky.  What's more, following years of big gains in the equity markets, stock prices for many of the best dividend payers is in the clouds.
• 02/08/2022

Dividend Income Summary: Lanny's January 2022 Summary

• Dividend Income Summary: Lanny's January 2022 Summary
• 02/07/2022

Here's My Top Value Stock to Buy Right Now

• It's exceptionally cheap and is defying the market downturn so far this year.
• 02/07/2022

2 Reasons To Buy Viatris Stock, and 1 Reason to Sell

• It's shaping up to be a compelling dividend stock.
• 02/05/2022

Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease

• Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.
• 02/04/2022

Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

• PITTSBURGH, Feb. 4, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will host its investor event the morning of Monday, February 28, 2022, beginning at 8:30 a.m. ET. During the event, Chief Executive Officer Michael Goettler , President Rajiv Malik  and Chief Financial Officer Sanjeev Narula  will share the company's financial results for the fourth quarter and full year 2021 and will provide additional detail on the company's two-phased strategic roadmap.
• 02/04/2022

Viatris Hiked Its Dividend: Is It a Buy?

• The generic drug manufacturer recently rewarded shareholders with a massive dividend hike.
• 02/02/2022

Is Viatris a Value Trap?

• This drugmaker might appeal to certain types of investors.
• 02/01/2022

2 Dirt-Cheap Value Stocks to Buy Now

• These two dividend-paying pharma stocks ought to be top performers in 2022.
• 01/29/2022

Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know

• In the latest trading session, Viatris (VTRS) closed at $14.36, marking a -1.17% move from the previous day.
• 01/24/2022

Prepare For Takeoff On These 2 Great Bargains

• The recent market sell-off has created even better bargains across value stocks. I highlight 2 stocks that provide good diversification and value.
• 01/23/2022

3 Dividend Stocks to Buy if the Market Crashes

• All three of these stocks share a key attribute: resiliency.
• 01/21/2022

Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label Risks

• Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection.  The Company cited the risk of the label is missing on some prefilled pens contained inside labeled cartons of the drug.
• 01/20/2022

4 Stocks for When Real Interest Rates Are Rising

• Increasing real rates can hurt stocks in several ways, but so-called quality value stocks can thrive.
• 01/20/2022

Viatris: Cheap Stock, Solid Dividend Yield, And Impressive Free Cash Flow

• Viatris: Cheap Stock, Solid Dividend Yield, And Impressive Free Cash Flow
• 01/20/2022

Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know

• In the latest trading session, Viatris (VTRS) closed at $15.22, marking a +1.33% move from the previous day.
• 01/17/2022

Why Shares of Viatris Fell 27.8% in 2021

• The company, formed by the merger of Mylan and the Upjohn division of Pfizer, has underwhelmed investors.
• 01/12/2022

Viatris: Prepare For Takeoff

• Viatris appears to be trading in bargain-basement territory at present. It has demonstrated stable business performance, and the biosimilars pipeline and cost synergies could be catalysts for 2022.
• 01/11/2022

Jim Cramer's 2022 outlook for the S&P 500's 10 biggest losers in 2021

• The "Mad Money" host said poor 2021 performers such as Penn National and Global Payments are likely to keep struggling this year.
• 01/03/2022

7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now

• These cheap stocks are trading at highly attractive prices and have the potential to break through this year. The post 7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now appeared first on InvestorPlace.
• 01/03/2022

A 2021 Year-End Portfolio Of Bounce Candidates Expected To Outperform In January

• Retail tax loss selling and institutional portfolio window dressing can artificially depress underperforming stocks in the final trading days of the calendar year. Buying a basket of underperformers, the goal is to outperform the S&P 500 by five percentage points at some point during January 2022.
• 12/30/2021

3 Ultra-Cheap Stocks to Buy Right Now

• They could be great value buys heading into 2022.
• 12/28/2021

3 Healthcare Stocks to Buy and Hold for the Next 10 Years

• Their products are indispensible, and their continued growth is nearly guaranteed.
• 12/28/2021

Better Buy: Viatris vs. AbbVie

• Both face headwinds -- and future opportunities.
• 12/21/2021

Viatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results

• PITTSBURGH, Dec. 17, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that it will move its investor event previously scheduled for Friday, January 7, 2022 to no later than February 28, 2022 in conjunction with the release of its fourth quarter 2021 results. The Company also reiterated its 2021 financial guidance, previously provided on November 8, 2021.
• 12/17/2021

Dividend Stock Purchase: Lanny's November 2021 Summary

• I invested quite a bit into the VYM ETF. This has helped me amass an investment with Vanguard of over $40,000+ since last year!
• 12/16/2021

7 of the Best Value Stocks for 2022 to Buy Now

• Value stocks are not always winners. That's on full display with the scores of "value traps" that leave investors with big regret and poor performance.
• 12/15/2021

Will Adding Viatris Help Unlock the Value in Biocon?

• Investors looking to take advantage of the large and rapidly growing market for biosimilar drugs might want to keep an eye on a potential deal cooking between the Pfizer Inc. ( PFE , Financial) spinoff Viatris Inc. ( VTRS , Financial) and an Indian biosimilar company called Biocon Limited (BIOCON.NS).
• 12/12/2021

Viatris Stock: A Potential Cash Cow At An Attractive Entry Point

• Viatris Inc. is a pharmaceutical company formed through the merger between Mylan and Upjohn, a division of Pfizer (PFE), on 16 November 2020.
• 12/10/2021

Viatris Is A Strong Buy

• Viatris is down 30% since I rated it as a buy. The fundamentals have not changed, and the company is revising its guidance upward.
• 12/10/2021

6 Dividend Increases Expected In December 2021

• 6 Dividend Increases Expected In December 2021
• 12/07/2021

3 Beaten-Down Dividend Stocks -- Are They Bargins Now?

• Rising quarterly payouts and above-average yields make these dividend stocks worthy of your immediate attention.
• 12/06/2021

Viatris Inc. (VTRS) CEO Michael Goettler Presents at 4th Annual Evercore ISI HealthCONx Virtual Brokers Conference (Transcript)

• Viatris Inc. (VTRS) CEO Michael Goettler Presents at 4th Annual Evercore ISI HealthCONx Virtual Brokers Conference (Transcript)
• 12/01/2021

7 Drug Stocks to Buy Now While They're Still on Sale

• Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. The post 7 Drug Stocks to Buy Now While They're Still on Sale appeared first on InvestorPlace.
• 11/30/2021

Is It Too Late to Buy Viatris Stock?

• It's not too late if you're looking for dividend income.
• 11/30/2021

Dividend Stock Watch List: Lanny's December 2021 Edition

• The stock market, specifically the S&P 500, still is high, but is down for the month of November so far.
• 11/29/2021

3 Pharma Stocks That Are Too Cheap to Ignore

• Many stocks are ridiculously expensive right now -- but not these three.
• 11/25/2021

2 Cheap Pharma Stocks That Pay A Tidy Dividend

• These stocks are unlikely to beat the market, but they're great for dividend income.
• 11/22/2021

3 Things About Viatris That Smart Investors Know

• Don't expect it to follow the trajectory of a hot growth stock.
• 11/21/2021

3 Top Biotech Stocks to Buy Right Now

• These three biotech stocks will do well with a growing and aging customer base in the decades ahead.
• 11/13/2021

Viatris Is A Compelling Deep Value Pick

• Viatris is a well-positioned manufacturer of legacy brand products, generics and biosimilars with a promising pipeline.
• 11/12/2021

The Smartest Stocks to Buy With $20 Right Now

• A small amount of money can go a long way when invested in these top-notch stocks.
• 11/12/2021

Should I buy Viatris shares after a strong Q3 report?

• Viatris Inc. (NASDAQ: VTRS) shares have advanced more than 5% after the company reported better than expected third-quarter results on Monday. Viatris's business continued to grow throughout the third fiscal quarter, and the company's management raised financial guidance for the full fiscal year during the third-quarter earnings call.
• 11/09/2021

Viatris Inc. (VTRS) CEO Michael Goettler on Q3 2021 Results - Earnings Call Transcript

• Viatris Inc. (VTRS) CEO Michael Goettler on Q3 2021 Results - Earnings Call Transcript
• 11/08/2021

Viatris (VTRS) Beats on Q3 Earnings & Sales, Tweaks View

• Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance.
• 11/08/2021

Viatris: A Look At Whether Q3 Sales Can Tilt The Scales

• Viatris delivered good revenues and free cash flow and raised guidance for the year. Deleveraging has gone well so far in 2021, but has the financial position actually improved?
• 11/08/2021

Viatris (VTRS) Q3 Earnings and Revenues Surpass Estimates

• Viatris (VTRS) delivered earnings and revenue surprises of 15.12% and 3.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
• 11/08/2021

Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?

• Viatris' (VTRS) Q3 earnings might have gained from the solid performance of Viagra, Dymista, and the Thrombosis portfolio.
• 11/02/2021

Fortune's Change The World Report Included 5 Ideal Dividend Dogs

• A special report in Fortune Magazine October/November 2021 listed 53 Change The World (CTW) companies using plain old capitalism (including profits) to "address society's unmet needs."
• 10/28/2021

2 Dividend Stocks That Are Dirt Cheap Right Now

• The market is deeply discounting this pair of income-generating stocks, which should keep delivering for years to come.
• 10/25/2021

There's Money to Be Made With Vertex, Viatris, Incyte and Biogen

• A screening of healthcare stocks in the S&P 500 reveals that investors may find plenty of upside in three members of the index, according to an article in Barron's. The analysis showed that Vertex Pharmaceuticals ( VRTX , Financial), Viatris Inc. ( VTRS , Financial) and Incyte Corp. ( INCY , Financial) all sell at deep discounts to price forecasts by Wall Street analysts.
• 10/24/2021

Could Viatris Stock Help You Retire a Millionaire?

• It depends on how much help you're looking for.
• 10/23/2021

3 Dirt-Cheap Stocks Wall Street Thinks Will Soar 43% to 80%

• Analysts are bullish about these bargains.
• 10/22/2021

Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris